Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 4/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.35 |
| ▸ | FDPS | P14324 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citronellyl Acetate SCHEMBL157075 | 0.93 | ALOX15 (1.00) | ALOX15ALDH1A1NFE2L2EPHX2USP2 | |
| Citronellyl Acetate SCHEMBL1866109 | 0.93 | ALOX15 (1.00) | ALOX15ALDH1A1NFE2L2EPHX2USP2 | |
| Citronellyl Acetate SCHEMBL20912959 | 0.93 | ALOX15 (1.00) | ALOX15ALDH1A1NFE2L2EPHX2USP2 | |
| Citronellyl Acetate SCHEMBL3666360 | 0.92 | ALOX15 (0.73) | ALOX15ALDH1A1NFE2L2EPHX2USP2 | |
| Citronellyl Acetate SCHEMBL2464823 | 0.90 | ALOX15 (0.93) | ALOX15ALDH1A1NFE2L2EPHX2USP2 | |
| Citronellyl Acetate SCHEMBL27652840 | 0.87 | ALOX15 (0.87) | ALOX15ALDH1A1NFE2L2EPHX2USP2 | |
| Citronellyl Acetate SCHEMBL6293315 | 0.87 | ALOX15 (0.87) | ALOX15ALDH1A1NFE2L2EPHX2USP2 | |
| Citronellyl Acetate SCHEMBL10961285 | 0.87 | ALOX15 (0.87) | ALOX15ALDH1A1NFE2L2EPHX2USP2 | |
| Citronellol SCHEMBL8024693 | 0.86 | ALOX15 (0.65) | ALOX15ALDH1A1NFE2L2EPHX2USP2 | |
| SCHEMBL7553169 | 0.86 | ALOX15 (0.61) | ALOX15ALDH1A1TSHRPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240041752-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2024-02-08 | — | — | US | disclosed |
| US-10265249-B2 | Fibrous structures comprising glyceride copolymers | THE PROCTER & GAMBLE COMPANY (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180085288-A1 | FIBROUS STRUCTURES COMPRISING GLYCERIDE COPOLYMERS | THE PROCTER & GAMBLE COMPANY | 2018-03-29 | — | — | US | disclosed |
| EP-0977548-B2 | FRAGRANCE PRO-ACCORDS | PROCTER & GAMBLE (US) | 2008-03-26 | — | — | EP | disclosed |
| EP-1171566-B1 | PRO-FRAGRANCES | PROCTER & GAMBLE (US) | 2004-12-22 | — | — | EP | disclosed |
| EP-0977548-B1 | FRAGRANCE PRO-ACCORDS | PROCTER & GAMBLE (US) | 2004-08-18 | — | — | EP | disclosed |
| US-6551987-B1 | For delivering fragrance raw material ketones, preferably alpha , beta -unsaturated ketones, inter alia, damascones, ionones to human skins | THE PROCTER & GAMBLE COMPANY | 2003-04-22 | — | — | US | disclosed |
| EP-1171566-A1 | PRO-FRAGRANCES | THE PROCTER & GAMBLE COMPANY (US) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000063339-A1 | PRO-FRAGRANCES | THE PROCTER & GAMBLE COMPANY (US) | 2000-10-26 | — | — | WO | disclosed |
| US-6114302-A | STABILITY | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-05 | — | — | US | disclosed |
| US-6077821-A | FOR USE IN DELIVERING SUSTAINED RELEASE OR ENHANCED LONGEVITY FRAGRANCES TO A VARIETY OF PERSONAL CARE AND PERSONAL HYGIENE PRODUCTS INTER ALIA DEODORANTS, BODY LOTIONS OR CREAMS, AND SHAMPOOS | THE PROCTER & GAMBLE COMPANY (US) | 2000-06-20 | — | — | US | disclosed |
| EP-0977549-A1 | PERFUMES HAVING ODOR LONGEVITY BENEFITS | THE PROCTER & GAMBLE COMPANY (US) | 2000-02-09 | — | — | EP | disclosed |
| EP-0977548-A1 | FRAGRANCE PRO-ACCORDS | THE PROCTER & GAMBLE COMPANY (US) | 2000-02-09 | — | — | EP | disclosed |
| US-6013618-A | ORTHOESTERS, KETALS, ACETALS, ORTHOCARBONATES WHICH RELEASE TWO OR MORE FRAGRANCE RAW MATERIALS UPON HYDROLYSIS | PROCTER & GAMBLE COMPANY (US) | 2000-01-11 | — | — | US | disclosed |
| US-5919752-A | ORTHOESTERS, KETALS, ACETALS, ORTHOCARBONATES WHICH RELEASE TWO OR MORE FRAGRANCE RAW MATERIALS UPON HYDROLYSIS. | PROCTER & GAMBLE (US) | 1999-07-06 | — | — | US | disclosed |
| WO-1999021954-A1 | LAUNDRY COMPOSITIONS HAVING REDUCED MALODOR AND METHODS FOR PROVIDING THE SAME | THE PROCTER & GAMBLE COMPANY (US) | 1999-05-06 | — | — | WO | disclosed |
| WO-1998047996-A1 | LAUNDRY DETERGENT COMPOSITIONS COMPRISING FRAGRANCE PRO-ACCORDS | THE PROCTER & GAMBLE COMPANY (US) | 1998-10-29 | — | — | WO | disclosed |
| WO-1998047477-A1 | FRAGRANCE PRO-ACCORDS | THE PROCTER & GAMBLE COMPANY (US) | 1998-10-29 | — | — | WO | disclosed |
| WO-1998047478-A1 | PERFUMES HAVING ODOR LONGEVITY BENEFITS | THE PROCTER & GAMBLE COMPANY (US) | 1998-10-29 | — | — | WO | disclosed |
| US-4218348-A | PERFUMES | SHELL OIL COMPANY (US) | 1980-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10265249-B2 | Fibrous structures comprising glyceride copolymers | FIBP, PHOSPHO1, FN1 | ALOX15 2988/4885ALDH1A1 3580/4885NFE2L2 4885/4885 |
| US-20180085288-A1 | FIBROUS STRUCTURES COMPRISING GLYCERIDE COPOLYMERS | FIBP, PHOSPHO1, FN1 | ALOX15 2988/4885ALDH1A1 3580/4885NFE2L2 4885/4885 |
| US-20240041752-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | AOX1, TYR, OCIAD1 | ALOX15 158/4885ALDH1A1 116/4885NFE2L2 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.